ASH 2022 Post Conference Perspectives: Evolutions in the Treatment of Myelodysplastic Syndromes (MDS)

home / post-conference-perspectives / ash-2022-post-conference-perspectives-evolutions-in-the-treatment-of-myelodysplastic-syndromes

Guillermo Garcia-Manero, MD, provides insights surrounding myelodysplastic syndrome (MDS) from the ASH 2022 Annual Meeting and Exposition.

Episodes

Guillermo Garcia-Manero, MD, highlights the ASCERTAIN trial in his opening thoughts surrounding MDS in this ASH 2022 post-conference perspective.

Dr Garcia-Manero discusses the effects of TP53 mutation in patients with MDS.

Treatment strategies for patients with lower-risk MDS are examined.

In his closing thoughts, Dr Garcia-Manero provides an overview of the treatment management approach for patients with MDS.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512